Vanishing bile duct syndrome in drug-induced liver disease

Journal of Hepatology, Supplement

Volumn 26, Issue 1, 1997, Pages 31-35

  Desmet, V J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIN;

BILE DUCT DISEASE; CHEMICALLY INDUCED DISORDER; CHOLESTASIS; HUMAN; IATROGENIC DISEASE; REVIEW; SCLEROSING CHOLANGITIS; SYNDROME; TOXIC HEPATITIS;

BILE DUCT DISEASES; CHOLANGITIS, SCLEROSING; CHOLESTASIS; HEPATITIS, TOXIC; HUMANS; IATROGENIC DISEASE; SYNDROME; TOXINS, BIOLOGICAL;

EID: 0030626785     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(97)82330-6     Document Type: Article

References (50)

1. Desmet VJ. Vanishing bile duct disorders. In: Boyer JL, Ockner RK, eds. Progress in Liver Diseases, Vol. X. Philadelphia: WB Saunders, 1992; 89-121.
2. Altraif I, Lilly L, Wanless IR, Heathcote J. Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim - sulfamethoxazole. Am J Gastroenterol 1994; 89: 1230-4.
3. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, Moreau A, Potet F, Benhamou JP. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992; 15: 244-51.
4. Van Eyken P, Desmet VJ. Bile duct cells. In: LeBouton AV, ed. Molecular and Cell Biology of the Liver, Boca Raton: CRC Press, 1993; 475-524.
5. Hubscher SG, Buckels JAC, Elias E, McMaster P, Neuberger J. Vanishing bile duct syndrome following liver transplantation - is it reversible? Transplantation 1991; 51: 1004-10.
6. Larrey D, Erlinger S. Drug-induced cholestasis. Baillieres Clin Gastroenterol 1988; 2: 423-52.
7. Brown PJE, Lesna M, Hamlyn AN, Record CO. Primary biliary cirrhosis after long-term practolol administration. Br Med J 1978; 1: 1591.
8. Farrell GC. Drug-induced Liver Disease, Edinburgh: Churchill Livingstone, 1994.
9. Reichen J. Diagnostic approach to cholestasis. J Hepatol 1996; 25 (Suppl 1): 41-6.
10. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994; 107: 1844-7.
11. Ishii M, Miyazaki Y, Yamamoto T, Miura M, Ueno Y, Takahashi T, Toyoto T. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver 1993; 13: 227-31.
12. Bénichou C. Criteria of drug-induced liver disorders. Report of an international Consensus Meeting. J Hepatol 1990; 11: 272-6.
13. Zimmerman HJ. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. New York: Appleton Century Crofts, 1978.
14. Read AE, Harrison CV, Sherlock S. Chronic chlorpromazine jaundice. With particular reference to its relationship to primary biliary cirrhosis. Am J Med 1961; 31: 249-58.
15. Manivel JC, Bloomer JR, Snover DC. Progressive bile duct injury after Thiabendazole administration. Gastroenterology 1987; 93: 245-9.
16. Hautekeete ML, Brenard R, Horsmans Y, Henrion J, Verbist L, Derue G, Druez P, Omar M, Kockx M, Hubens H, Haber I, Rahier J, Geubel A. Liver injury related to amoxycillin-clavulanic acid: interlobular bile-duct lesions and extrahepatic manifestations. J Hepatol 1995; 22: 71-7.
17. Hall PdlM. Histopathology of drug-induced liver disease. In: Farrell GC, ed. Drug-induced Liver Disease, Edinburgh: Churchill Livingstone, 1994; 115-51.
18. Bianchi L. Intrahepatic bile duct damage in various forms of liver diseases. In: Brunner H, Thaler H, eds. Hepatology. A Festschrift for Hans Popper. New York: Raven Press, 1985; 295-310.
19. Van Eyken P, Desmet VJ. Cytokeratins and the liver. Liver 1993; 13: 113-22.
20. Desmet VJ. Pathology of paediatric cholestasis. In: Lentze M, Reichen J, eds. Paediatric Cholestasis. Novel Approaches to Treatment. Dordrecht: Kluwer Academic Publishers, 1992; 55-73.
21. Desmet VJ. Cholestasis: extrahepatic obstruction and secondary biliary cirrhosis. In: MacSween RNM, Anthony PP, Scheuer PJ, Burt AD, Portmann BC, eds. Pathology of the Liver, 3rd edn. Edinburgh: Churchill Livingstone, 1994; 425-76.
22. Ludwig J, Wiesner RH, La Russo NF. Idiopathic adulthood ductopenia. A cause of chronic cholestatic liver disease and biliary cirrhosis. J Hepatol 1988; 7: 193-9.
23. Alagille D, Odièvre M, Gautier M, Dommergues JP. Hepatic ductular hypoplasia associated with characteristic facies, vertebral malformations, retarded physical, mental and sexual development and cardiac murmur. J Pediatr 1975; 86: 63-71.
24. Moradpour D, Altorfer J, Flury R, Greminger P, Meyenberger C, Jost T, Schmid M. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994; 20: 1437-41.
25. Gregory DH, Zaki GF, Sarcosi GA, Carey JBJ. Chronic cholestasis following prolonged tolbutamide administration. Association with destructive cholangitis and cholangiolitis. Arch Pathol 1967; 84: 194-201.
26. Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992; 15: 154-61.
27. Glober GA, Wilkenson JA. Biliary cirrhosis following administration of methyltestosterone. JAMA 1968; 204: 170-3.
28. Yamada S, Howe S, Scheuer PJ. Three-dimensional reconstruction of biliary pathways in primary biliary cirrhosis: a computer-assisted study. J Pathol 1987; 152: 317-23.
29. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988; 81: 569-78.
30. Campbell CB, McGuffie C, Weedon AP, Powell LW. Cholestatic liver disease associated with diphenylhydantoin therapy: possible pathogenetic importance of altered bile salt metabolism. Am J Dig Dis 1977; 22: 255-62.
31. King PB, Blitzer BL. Drug-induced cholestasis: pathogenesis and clinical features. Semin Liver Dis 1990; 10: 316-21.
32. Kopelman H, Scheuer PJ, Williams R. The liver lesion of the Epping jaundice. Q J Med 1966; 25: 553-64.
33. McGill DB, Motto JP. An industrial outbreak of toxic hepatitis due to methylene-diamine. N Engl J Med 1974; 291: 278-81.
34. Solis-Herruzo JA, Castellano G, Colina F, Morillas JD, Munoz-Yagüe MT, Del Carmen Coca M, Jelavic D. Hepatic injury in the toxic epidemic syndrome caused by ingestion of adulterated cooking oil (Spain 1981). Hepatology 1984; 4: 131-9.
35. Mullick FG, Ishak KG, Mahabir R, Stromeyer FW. Hepatic injury associated with paraquat toxicity in humans. Liver 1981; 1: 209-21.
36. Matsumoto T, Matsumori H, Kuwabara N, Fukuda Y, Ariwa R. A histopathological study of the liver in paraquat poisoning - an analysis of fourteen autopsy cases with emphasis on bile duct injury. Acta Pathol Jpn 1980; 30: 859-70.
37. Goldfarb S, Singer EJ, Popper H. Experimental cholangitis due to alpha-naphthylisothiocyanate (ANIT). Am J Pathol 1962; 40: 685-98.
38. Bhathal PS, Jordan TW, Mackay IR. Mouse strain differences in susceptibility to sporidesmin-induced biliary tract injury. Liver 1990; 10: 193-204.
39. Batzinger RP, Bueding E, Popper H. Protection by antibiotics against experimental focal cholangitis produced in mice by a schistosomicidal isothiocyanate. Hepatology 1981; 1: 21-7.
40. Hohn D, Melnick J, Stagg R, Altman D, Friedmann M, Ignoffo R, Ferrell L, Lewis B. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3: 98.
41. Shea WJ, Demas BE, Goldberg HI, Hohn DC, Ferrell LD, Kerlan RK. Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation. AJR Am J Roentgenol 1986; 146: 717-21.
42. Kemeny MM, Battifora H, Blayney DW, Cecchi G, Goldberg DA, Leong LA, Margolin KA, Terz JJ. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202: 176-81.
43. Bolton JS, Bowman JC. Biliary sclerosis associated with hepatic artery infusion of floxuridine. Surgery 1986; 99: 119-22.
44. Anderson SD, Holley HC, Berland LL, Van Dyke JA, Stanley RJ. Causes of jaundice during hepatic artery infusion chemotherapy. Radiology 1986; 161: 439-42.
45. Castellano G, Moreno-Sanchez D, Gutierrez J, Moreno-Gonzalez E, Colina F, Solis-Herruzo JA. Caustic sclerosing cholangitis. Report of four cases and a cumulative review of the literature. Hepatogastroenterology 1994; 41: 458-70.
46. Ludwig J, Kim CH, Wiesner RH, Krom RA. Floxuridine induced sclerosing cholangitis: an ischemic cholangiopathy. Hepatology 1989; 9: 215-8.
47. Northover JMA, Terblanche J. A new look at the arterial supply of the bile ducts in man and its surgical implications. Br J Surg 1979; 66: 379-84.
48. Farrell GC. Biochemical mechanisms. In: Farrell GC, ed. Drug-induced Liver Disease. Edinburgh: Churchill Livingstone, 1994; 23-60.
49. Belghiti J, Benhamou JP, Houry S, Drenier P, Huguier M, Fekete F. Caustic sclerosing cholangitis: a complication of the surgical treatment of hydatid disease of the liver. Arch Surg 1986; 121: 1162-5.
50. Ludwig J. New concepts in biliary cirrhosis. Semin Liver Dis 1987; 7: 293-301.